Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH.
Kaplan
Steven A
SA
Institute of Bladder and Prostate Health, Weill Cornell Medical College, Cornell University, New York, USA. kaplans@med.cornell.edu
Hatzichristou
Dimitrios
D
D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D014555:Urination Disorders / Q000188:drug therapy / Q000209:etiology
D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors